drugset / Trial / NCT01515020

Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

NCT01515020

RandomizedParallel-groupOpen-labelTreatment

Summary

Hypothesis: The use of daptomycin to treat nosocomial or healthcare-associated bacteremia due to methicillin-resistant S. aureus (MRSA) would increase the proportion of patients whose blood cultures are sterilized after 72 hours by 15% relative to vancomycin and would improve treatment safety. Hypothesis: for MRSA nosocomial or healthcare related bacteriemia treatment, the use of daptomycin versus vancomycin would increase by 15% the proportion of patients with sterilized blood cultures at 72 hours and would increase the treatment safety. Primary objective: To study the efficacy of daptomycin compared to vancomycin on the sterilization of blood cultures after 72 hours of therapy.

Timeline

Start
2012-05
Primary completion
2013-06
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 10 mg/kg Intravenous
Comparator Vancomycin Other / unclassified Intravenous

Indications